SUMMIT, N.J.--(BUSINESS WIRE)--
2007 Third Quarter Financial Results Year-Over-Year:
Total Revenue Increased 43 Percent to $350 Million
Product Sales Increased 48 Percent to $331 Million
REVLIMID® Net Product Sales Increased 97 Percent to $199 Million
THALOMID® Net Product Sales Increased to $111 Million
Adjusted Operating Income Increased 84 Percent to $146 Million
Adjusted Net Income Increased 109 Percent to $124 Million
Adjusted Earnings Per Share Increased 93 Percent to $0.29 Per Diluted Share
